US puts $25m behind Cellino's cell and tissue printing tech
Newsletters and Deep Dive digital magazine
Sage Therapeutics has launched another round of layoffs as it deals with the fallout of abandoning a key pipeline drug for Alzheimer's and Parkinson's disease.
Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease